Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2007-03-27
2007-03-27
Kemmerer, Elizabeth (Department: 1649)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S139100, C530S387300, C530S388850
Reexamination Certificate
active
10226435
ABSTRACT:
A method to treat conditions characterized by formation of amyloid plaques both prophylactically and therapeutically is described. The method employs humanized antibodies which sequester soluble Aβ peptide from human biological fluids or which preferably specifically bind an epitope contained within position 13–28 of the amyloid beta peptide Aβ.
REFERENCES:
patent: 5004697 (1991-04-01), Pardridge
patent: 5278049 (1994-01-01), Baker et al.
patent: 5593846 (1997-01-01), Schenk et al.
patent: 5688651 (1997-11-01), Solomon
patent: 5693762 (1997-12-01), Queen et al.
patent: 5753624 (1998-05-01), McMichael et al.
patent: 5766846 (1998-06-01), Schlossmacher et al.
patent: 5837672 (1998-11-01), Schenk et al.
patent: 5837822 (1998-11-01), Gallatin et al.
patent: 5851996 (1998-12-01), Kline
patent: 5935927 (1999-08-01), Vitek et al.
patent: 6037454 (2000-03-01), Jardieu et al.
patent: 6114113 (2000-09-01), McLaughlin-Taylor et al.
patent: 6218506 (2001-04-01), Krafft et al.
patent: 2002/0009445 (2002-01-01), Yansheng et al.
patent: 2002/0058267 (2002-05-01), Ozenberger et al.
patent: 2002/0086847 (2002-07-01), Chain
patent: 2002/0102261 (2002-08-01), Raso
patent: 0613007 (1994-02-01), None
patent: WO89/01343 (1989-02-01), None
patent: WO96/18900 (1996-06-01), None
patent: WO96/25435 (1996-08-01), None
patent: WO98/33815 (1998-08-01), None
patent: WO98/44955 (1998-10-01), None
patent: WO99/27944 (1999-06-01), None
patent: WO99/06066 (1999-11-01), None
patent: WO99/60024 (1999-11-01), None
patent: WO00/72876 (2000-12-01), None
patent: WO00/72880 (2000-12-01), None
patent: WO00/77178 (2000-12-01), None
patent: WO01/10900 (2001-02-01), None
patent: WO01/18169 (2001-03-01), None
patent: WO02/021141 (2002-03-01), None
patent: WO02/046237 (2002-06-01), None
patent: WO02/060481 (2002-08-01), None
Shefner et al., J. Exp. Med., 173:287-296, 1991, lg kappa(light) chain v region.
Adair et al., WO 91/09967.
Raaphorst et al., Eur. J. Immunol., 22, 247-251, 1992, lg heavy chain.
Strbak, V. et al. “Passive Immunization and Hypothalamic peptide Secretion”, Neuroendocrinology 1993; 58:210-217.
Ragusi, C. et al. “Redistribution of Imipramine from Regions of the Brain Under the Influence of Circulating Specific Antibodies” J. Neurochem., vol. 70, No. 5, pp. 2099-105 (1998) The form should be signed and dated by.
Suo, Z. et al., “Soluble Alzhelmers β-amyloid constricts the cerebral vasculature in vivo” Neuroscience Letters 257, pp. 77-80 (1998).
Lue, L. et al., “Soluble β-amyloidPeptide Concentration as a Predictor of Synaptic Change in Alzheimer's Disease”, Am. J. Pathol. 1999, 155: pp. 853-62.
Teller, J. et al. “Presence of soluble amyloid β-peptide precedes amyloid plague formation in Down's syndrome” Nature Medicine, vol. 2, No. 1, pp. 93-95 (1996).
Esler, W. et al. “Point substitution in the central hydrophobic cluster of a human β-amyloid congener disrupts peptide folding and abolishes plaque competence” Biochemistry, vol. 35, pp. 13914-21 (1996).
Maggio, J. & Mantyh, P. “Brain Amyloid—A Physicochemical Perspective” Brain Pathology, vol. 6, 147-162 (1996).
Gorevic, P. et al. “Ten to fourteen residue peptides of Alzheimer's disease protein are sufficient for amyloid fibril formation and its characteristic X ray diffraction pattern” Biochem. and Biophy. Res. Commun., vol. 147, No. 2 (1987).
Balbach, J. et al. “Amyloid fibril formation by Aβ16-22, a seven-residue fragment of the Alzheimer's β-amyloid peptide, and structural characterization by solid state NMR” Biochemistry, vol. 39, pp. 13748-59 (2000).
Simmons, L. “Secondary Structure of amyloid β peptide correlates with neurotoxic activityIn Vitro” Molecular Pharmacology, vol. 45, pp. 373-9 (1994).
Wood, A. et al. “Prolines and amyloidogenicity in fragments of the Alzheimer's peptide β/A4” Biochemistry, vol. 34 pp. 724-30 (1995).
Xu, S. and Gaskin, F. “Increased incidence of anti-β-amyloid autoantibodies secreted by Epstein-Barr virus transformed B cell lines from patients with Alzheimer's disease” Mechanisms of Ageing and Development, vol. 94, pp. 213-22 (1997).
Soto, C. et al. “The α-helical to β-strand transition in the amino-terminal fragment of the amyloid β-peptide modulates amyloid formation” J. Biol. Biol. Chem, vol. 270, No. 7, pp. 3063-67 (1995).
Tjernberg, L. et al. “A molecular model for Alzheimer amyloid β-peptide fibril formation” J. Biol. Biol. Chem, vol. 274, No. 18, pp. 12619-25 (1999).
Hilbich, C. et al. “Substitutions of hydrophobic amino acid reduce the amyloidogenicity of Alzheimer's disease βA4 peptides” J. Mol. Biol., vol. 228, pp. 460-73 (1992).
Hilbich, C. et al. “Human and rodent sequence analogs of Alzheimer's amyloid βA4 share similar properties and can be solubized in buffers of pH 7.4” Eur. J. Biochem., vol. 201, pp. 61-69 (1991).
Hilbich, C. et al. “Aggregation and secondary structure of synthetic amyloid βA4 peptides of Alzheimer's disease” J. Mol. Biol., vol. 218, pp. 149-163 (1991).
Levitt M, “Molecular dynamics of native protein,”J Mol Biol, 168:595-620 (1983).
Queen C et al., “A humanized antibody that binds to the interleukin 2 receptor,”Proc Natl Acad Sci USA, 8610029-10033 (1989).
Burdick D et al., “Assembly and aggregation properties of synthetic Alzheimer's A4/β amyloid peptide analogs,”J Biol Chem, 267:546-55 (1992).
Co MS et al., “Chimeric and humanized antibodies with specificity for the CD33 antigen,”J Immunol, 148:1149-1154 (1992).
Ghiso J et al., “Epitope map of two polyclonal antibodies that recognize amyloid lesions in patients with Alzheimer's disease,”Biochem J, 282 (pt 2):517-522 (1992).
Haass C et al., “Amyloid beta-peptide is produced by cultured cells during normal metabolism,”Nature, 359:322-5 (1992).
Seubert P et al., “Isolation and quantification of soluble Alzheimer's β peptide from biological fluids,”Nature, 359:325-327 (1992).
Gaskin F et al., “Human antibodies reactive with beta-amyloid protein in Alzheimer's disease,”J Exp Med, 177(4):1181-1186 (1993).
Flood JF et al., “An amyloid β -protein fragment, A β [12-28], equipotently impairs post-training memory processing when injected into different limbic system structures,”Brain Res, 663(2):271-276 (1994).
Koudinov A et al., “The soluble form of Alzheimer's amyloid beta protein is complexed to high density lipoprotein 3 and very high density lipoprotein in normal human plasma,”Biochem&Biophysic Res Comm, 205:1164-1171 (1994).
Schwarzman AL et al., “Transthyretin sequesters amyloid β protein and prevents amyloid formation,”Proc Natl Acad Sci, 91:8368-8372, (1994).
Tabaton M et al., “Soluble amyloid β-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid,”Biochem and Biophysi Res Comm, 200(3):1598-1603 (1994).
Walker LC et al., “Labeling of cerebral amyloid in vivo with a monoclonal antibody,”J Neuropathol Exp Neurol, 53(4):377-383 (1994).
Wisniewski T et al., “Alzheimer's disease and soluble A beta,”Neurobiol Aging, 15(2):143-52 Review (1994).
DeMattos RB et al., “Peripheral antio-Aβ antibody alters CNS and plasma Aβ clearance and decreases Aβ burden in a mouse model of Alzheimer's disease,”Proc Natl Acad Sci USA, 98(15):8850-8855 (1996).
Giulian D et al., “Specific domains of β-amyloid from Alzheimer plaque elicit neuron killing in human microglia,”J Neurosci, 16 (19):6021-6037 (1996).
Hanan E et al., “Inhibitory effect of monoclonal antibodies on Alzheimer's {tilde over (β)}amyloid peptide aggregation,”Int J Exp Clin Invest, 3:130-133 (1996).
Solomon B e
Bales Kelly R.
DeMattos Ronald
Holtzman David M.
Paul Steven M.
Tsurushita Naoya
Ballard Kimberly A.
Eli Lilly and Company
Kemmerer Elizabeth
Stewart Mark J.
Washington University
LandOfFree
Humanized antibodies that sequester abeta peptide does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Humanized antibodies that sequester abeta peptide, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Humanized antibodies that sequester abeta peptide will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3723440